Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

BACKGROUND: Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Oncol
Autori principali: Coleman, Robert L, Brady, Mark F, Herzog, Thomas J, Sabbatini, Paul, Armstrong, Deborah K, Walker, Joan L, Kim, Byoung-Gie, Fujiwara, Keiichi, Tewari, Krishnansu S, O'Malley, David M, Davidson, Susan A, Rubin, Stephen C, DiSilvestro, Paul, Basen-Engquist, Karen, Huang, Helen, Chan, John K, Spirtos, Nick M, Ashfaq, Raheela, Mannel, Robert S
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5715461/
https://ncbi.nlm.nih.gov/pubmed/28438473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30279-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi